SLRN

3.15

2.17% -0.07

Handel nachbörslich: 3.15

Acelyrin Inc (SLRN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt SLRN? Forum Prognose

Schlusskurs vom Vortag:

$3.22

Offen:

$3.18

24-Stunden-Volumen:

933.80K

Relative Volume:

1.33

Marktkapitalisierung:

$316.03M

Einnahmen:

Nettoeinkommen (Verlust:

$-299.80M

KGV:

-0.2599

EPS:

-12.1221

Netto-Cashflow:

$-217.49M

1W Leistung:

-2.48%

1M Leistung:

-28.89%

6M Leistung:

-20.85%

1J Leistung:

-55.76%

1-Tages-Spanne:

$3.105

$3.25

1-Wochen-Bereich:

$3.105

$3.60

52-Wochen-Spanne:

$3.105

$8.885

Acelyrin Inc Stock (SLRN) Company Profile

Firmenname

Acelyrin Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

805-871-4300

Adresse

4149 LIBERTY CANYON RD., AGOURA HILLS

Mitarbeiter

130

Twitter

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

SLRN's Discussions on Twitter

Vergleichen Sie SLRN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLRN Acelyrin Inc	3.15	316.03M	0	-299.80M	-217.49M	-2.84
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Acelyrin Inc Stock (SLRN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-14	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-07-08	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-12-13	Eingeleitet	Wells Fargo	Equal Weight
2023-12-08	Eingeleitet	Citigroup	Neutral
2023-09-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-09-05	Eingeleitet	H.C. Wainwright	Buy
2023-05-30	Eingeleitet	Jefferies	Buy
2023-05-30	Eingeleitet	Morgan Stanley	Overweight
2023-05-30	Eingeleitet	Piper Sandler	Overweight
2023-05-30	Eingeleitet	TD Cowen	Outperform

Alle ansehen

Acelyrin Inc Aktie (SLRN) Neueste Nachrichten

Dec 19, 2024

Fmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 19, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Fmr LLC - MarketBeat

Dec 19, 2024

Dec 15, 2024

Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 15, 2024

Dec 14, 2024

SLRN stock touches 52-week low at $3.18 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 13, 2024

Acelyrin (NASDAQ:SLRN) Earns “Neutral” Rating from HC Wainwright - Defense World

Dec 13, 2024

Dec 12, 2024

Acelyrin shares retain neutral rating despite trial setback By Investing.com - Investing.com UK

Dec 11, 2024

Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks

Dec 11, 2024

Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 11, 2024

Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha

Dec 11, 2024

Dec 10, 2024

Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch

Dec 10, 2024

Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch

Dec 10, 2024

Acelyrin announces izokibep trial did not meet primary endpoint - TipRanks

Dec 10, 2024

ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks

Dec 10, 2024

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times

Dec 10, 2024

Dec 09, 2024

Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha

Dec 09, 2024

Dec 07, 2024

Polar Asset Management Partners Inc. Sells 150,700 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Jacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 06, 2024

Nov 28, 2024

Acuta Capital Partners LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Nov 28, 2024

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Analysts - MarketBeat

Nov 22, 2024

Nov 18, 2024

HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada

Nov 15, 2024

Acelyrin discloses ValenzaBio acquisition financials - Investing.com India

Nov 15, 2024

Nov 14, 2024

TD Cowen maintains Buy rating on Acelyrin shares - Investing.com

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com

Nov 14, 2024

Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com

Nov 14, 2024